BridgeMD
Tests treatment safety and results for Breast Cancer (Locally Advanced or Metastatic)
Official title A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
ClinicalTrials.gov ID: NCT07612891
What this study is testing
What is INV-6452?
INV-6452 is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for breast cancer (locally advanced or metastatic).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) advanced/metastatic breast cancer or locally advanced/metastatic solid tumor.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Written informed consent obtained.
- Adult patients aged ≥ 18 years.
- Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression...
- Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ).
- Have RECIST 1.1-defined measurable lesions.
You likely can't join if
- Have a second primary malignancy.
- Patients with primary CNS tumors or CNS metastases with prior local treatment failure.
- Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug.
- Has undergone major surgery within 28 days prior to the first dose of study drug.
- Prior anti-tumor therapy-related toxicities have not recovered to protocol-specified grades.
- Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose.
See the full eligibility criteria
- Written informed consent obtained.
- Adult patients aged ≥ 18 years.
- Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression following standard-of-care therapy, are intolerant to standard treatment, or...
- Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ).
- Have RECIST 1.1-defined measurable lesions.
- Has a life expectancy of \> 3 months.
- ECOG performance status 0-1.
- Adequate marrow, liver and kidney function.
- Meet the study's specified contraceptive requirements.
- Have a second primary malignancy.
- Patients with primary CNS tumors or CNS metastases with prior local treatment failure.
- Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug.
- Has undergone major surgery within 28 days prior to the first dose of study drug.
- Prior anti-tumor therapy-related toxicities have not recovered to protocol-specified grades.
- Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose.
- Patients with other severe and persistent underlying medical conditions as assessed by the Investigator.
- Have protocol-defined clinically significant cardiovascular diseases.
- Prolonged QTcF interval.
- Have any medical conditions likely to impair digestion and absorption of the investigational product.
- Patients with poorly managed blood glucose levels and blood pressure.
- Clinically significant abnormal serum potassium or sodium as judged by the investigator.
- Have experienced a severe concurrent infection 14 days prior to the first dose of study drug.
- Confirmed infection with HIV, HBV or HCV.
- Are currently receiving any other investigation agent.
- Have received prior CDK2 inhibitors.
- Patients with known hypersensitivity to the study drug or any of its components.
- History of allogenic tissue or solid organ transplant.
- Are unwilling or unable to comply with procedures required in this protocol.
- Has other severe systemic diseases or for other reasons deemed ineligible for participation in this clinical trial by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.